This approach, in which structure and activity is not
linked to a specific protein target, can cause other difficulties and slow the progress of discovery, not least because of the difficulty of assessing relevant toxicity against host
mechanisms and the inability to use structure - guided drug -
design to drive Medicinal Chemistry progress.
One of our goals is to understand more precisely the
mechanisms involved in the response to treatments
designed for leukemia and lymphoma, two cancers
linked to overproduction of blood cells.